CL2014002411A1 - Compuestos derivados de 5-(aril-amino)-1-fenilpirido[4,3-d]pirimidina-2,4,7(1h,3h,4ah)-triona, inhibidores de mek; composicion farmaceutica; y su uso en trastornos inflamatorios, autoinmunes com,o anrtritis reumatoide o esclerosis multiple, hiperproliferativas como leucemias, neoplasmas o carcinomas - Google Patents

Compuestos derivados de 5-(aril-amino)-1-fenilpirido[4,3-d]pirimidina-2,4,7(1h,3h,4ah)-triona, inhibidores de mek; composicion farmaceutica; y su uso en trastornos inflamatorios, autoinmunes com,o anrtritis reumatoide o esclerosis multiple, hiperproliferativas como leucemias, neoplasmas o carcinomas

Info

Publication number
CL2014002411A1
CL2014002411A1 CL2014002411A CL2014002411A CL2014002411A1 CL 2014002411 A1 CL2014002411 A1 CL 2014002411A1 CL 2014002411 A CL2014002411 A CL 2014002411A CL 2014002411 A CL2014002411 A CL 2014002411A CL 2014002411 A1 CL2014002411 A1 CL 2014002411A1
Authority
CL
Chile
Prior art keywords
phenylpyridido
hyperproliferatives
trione
neoplasms
leukemias
Prior art date
Application number
CL2014002411A
Other languages
English (en)
Spanish (es)
Inventor
Venkata P Palle
Bravesh Dave
Samiron Phukan
Abhijit Datta Khoke
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Rejender Kumar Kamboj
Rakesh Kumar Banerjee
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CL2014002411A1 publication Critical patent/CL2014002411A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
CL2014002411A 2012-03-14 2014-09-12 Compuestos derivados de 5-(aril-amino)-1-fenilpirido[4,3-d]pirimidina-2,4,7(1h,3h,4ah)-triona, inhibidores de mek; composicion farmaceutica; y su uso en trastornos inflamatorios, autoinmunes com,o anrtritis reumatoide o esclerosis multiple, hiperproliferativas como leucemias, neoplasmas o carcinomas CL2014002411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14

Publications (1)

Publication Number Publication Date
CL2014002411A1 true CL2014002411A1 (es) 2015-04-06

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014002412A CL2014002412A1 (es) 2012-03-14 2014-09-12 Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CL2014002411A CL2014002411A1 (es) 2012-03-14 2014-09-12 Compuestos derivados de 5-(aril-amino)-1-fenilpirido[4,3-d]pirimidina-2,4,7(1h,3h,4ah)-triona, inhibidores de mek; composicion farmaceutica; y su uso en trastornos inflamatorios, autoinmunes com,o anrtritis reumatoide o esclerosis multiple, hiperproliferativas como leucemias, neoplasmas o carcinomas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014002412A CL2014002412A1 (es) 2012-03-14 2014-09-12 Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.

Country Status (35)

Country Link
US (5) US9573944B2 (OSRAM)
EP (2) EP2834236B1 (OSRAM)
JP (3) JP6093384B2 (OSRAM)
KR (4) KR102241111B1 (OSRAM)
CN (4) CN107698585A (OSRAM)
AP (2) AP3834A (OSRAM)
AU (4) AU2013234014B2 (OSRAM)
BR (1) BR112014022713B1 (OSRAM)
CA (2) CA2865164C (OSRAM)
CL (2) CL2014002412A1 (OSRAM)
CO (2) CO7160029A2 (OSRAM)
CR (2) CR20140464A (OSRAM)
CU (2) CU24335B1 (OSRAM)
DK (2) DK2834236T3 (OSRAM)
DO (2) DOP2014000203A (OSRAM)
EA (2) EA029768B1 (OSRAM)
ES (2) ES2741896T3 (OSRAM)
GE (2) GEP201706774B (OSRAM)
GT (2) GT201400195A (OSRAM)
IL (2) IL234559A (OSRAM)
IN (2) IN2014MN01754A (OSRAM)
MA (2) MA37400B1 (OSRAM)
MX (3) MX355526B (OSRAM)
MY (2) MY175950A (OSRAM)
NI (2) NI201400108A (OSRAM)
NZ (2) NZ629432A (OSRAM)
PE (2) PE20141974A1 (OSRAM)
PH (2) PH12014502040A1 (OSRAM)
PL (1) PL2834237T3 (OSRAM)
SG (2) SG11201405006PA (OSRAM)
TN (2) TN2014000356A1 (OSRAM)
TR (1) TR201811976T4 (OSRAM)
UA (2) UA114907C2 (OSRAM)
WO (2) WO2013136249A1 (OSRAM)
ZA (1) ZA201406186B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2865164C (en) 2012-03-14 2021-06-08 Lupin Limited Heterocyclyl compounds as mek inhibitors
KR102556118B1 (ko) 2012-06-13 2023-07-19 인사이트 홀딩스 코포레이션 Fgfr 억제제로서 치환된 트리사이클릭 화합물
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102469849B1 (ko) 2013-04-19 2022-11-23 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
PT3061747T (pt) * 2013-10-25 2021-05-04 Shanghai hengrui pharmaceutical co ltd Derivados pirídicos de cetona, método para preparar os mesmos e aplicação farmacêutica dos mesmos
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX388991B (es) 2015-02-20 2025-03-20 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr)
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN110167928A (zh) 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019122129A1 (en) 2017-12-21 2019-06-27 Boehringer Ingelheim International Gmbh Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
AU2020296914A1 (en) 2019-06-19 2021-12-23 Boehringer Ingelheim International Gmbh Anticancer combination therapy
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220106106A (ko) * 2019-07-30 2022-07-28 에드빈세 아베 뇌졸중 치료용 mek 억제제
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021245055A1 (en) * 2020-06-02 2021-12-09 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2022214594A1 (en) 2021-04-09 2022-10-13 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022221866A1 (en) * 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024543982A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体
CN118591540A (zh) 2021-12-01 2024-09-03 勃林格殷格翰国际有限公司 包含环状2-氨基-3-氰基噻吩的kras降解化合物
CN119013272A (zh) 2021-12-01 2024-11-22 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
US20250129096A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20240128852A (ko) 2021-12-01 2024-08-27 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
EA007395B3 (ru) * 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2545660C (en) 2003-11-19 2013-06-04 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
BRPI0511967B8 (pt) * 2004-06-11 2021-05-25 Japan Tobacco Inc derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
JP2012524114A (ja) 2009-04-21 2012-10-11 ノバルティス アーゲー Ｍｅｋ阻害剤としてのヘテロ環式化合物
CA2865164C (en) 2012-03-14 2021-06-08 Lupin Limited Heterocyclyl compounds as mek inhibitors

Also Published As

Publication number Publication date
US9428499B2 (en) 2016-08-30
DOP2014000204A (es) 2015-02-15
US9969731B2 (en) 2018-05-15
CR20140464A (es) 2014-11-28
JP2015514056A (ja) 2015-05-18
CN104203947A (zh) 2014-12-10
AP3859A (en) 2016-10-31
CO7170131A2 (es) 2015-01-28
MX355474B (es) 2018-04-16
CU24335B1 (es) 2018-04-03
UA114907C2 (uk) 2017-08-28
UA114906C2 (uk) 2017-08-28
US20150299186A1 (en) 2015-10-22
BR112014022713A2 (OSRAM) 2017-06-20
EA028232B1 (ru) 2017-10-31
NZ629432A (en) 2017-01-27
MX2014010928A (es) 2015-04-10
ES2684517T3 (es) 2018-10-03
SG11201405007QA (en) 2014-10-30
DK2834236T3 (da) 2019-08-26
AU2013234009B2 (en) 2016-10-27
GT201400195A (es) 2017-11-09
US9555035B2 (en) 2017-01-31
PH12014502040B1 (en) 2014-11-24
PL2834237T3 (pl) 2018-11-30
HK1206020A1 (en) 2015-12-31
GEP201706671B (en) 2017-05-25
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
ES2741896T3 (es) 2020-02-12
JP6093384B2 (ja) 2017-03-08
TR201811976T4 (tr) 2018-09-21
CU24272B1 (es) 2017-08-08
DOP2014000203A (es) 2015-02-15
EP2834237B1 (en) 2018-06-06
KR20140138911A (ko) 2014-12-04
AU2013234014A1 (en) 2014-09-25
CN108383836A (zh) 2018-08-10
PE20141974A1 (es) 2014-12-12
PH12014502041A1 (en) 2014-11-24
EA029768B1 (ru) 2018-05-31
CA2865164A1 (en) 2013-09-19
EP2834236B1 (en) 2019-05-22
MA37405A1 (fr) 2016-03-31
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
JP2015509975A (ja) 2015-04-02
US20170112840A1 (en) 2017-04-27
MX2014010925A (es) 2015-04-10
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
CN107698585A (zh) 2018-02-16
KR20140138910A (ko) 2014-12-04
NI201400107A (es) 2014-11-26
NZ629442A (en) 2016-12-23
EP2834236A1 (en) 2015-02-11
AU2013234009A1 (en) 2014-09-25
CN104271577A (zh) 2015-01-07
AP3834A (en) 2016-09-30
DK2834237T3 (en) 2018-08-27
WO2013136249A1 (en) 2013-09-19
JP2018115215A (ja) 2018-07-26
US9573944B2 (en) 2017-02-21
IL234559A (en) 2017-06-29
SG11201405006PA (en) 2014-10-30
CU20140110A7 (es) 2014-11-27
US20150133424A1 (en) 2015-05-14
US20160331753A1 (en) 2016-11-17
MY174188A (en) 2020-03-12
CA2865164C (en) 2021-06-08
IN2014MN01754A (OSRAM) 2015-07-03
EA201491671A1 (ru) 2014-12-30
AP2014008008A0 (en) 2014-10-31
PE20141973A1 (es) 2014-12-12
AU2018202568B2 (en) 2019-05-09
JP6431770B2 (ja) 2018-11-28
AU2018202568A1 (en) 2018-05-10
CN108383836B (zh) 2021-11-12
CL2014002412A1 (es) 2015-03-06
JP6630771B2 (ja) 2020-01-15
NI201400108A (es) 2014-11-28
MA37400A1 (fr) 2016-05-31
MX355526B (es) 2018-04-20
AU2017200493B2 (en) 2018-03-29
MX366426B (es) 2019-07-08
EP2834237A1 (en) 2015-02-11
KR102240101B1 (ko) 2021-04-14
IL234560A (en) 2017-06-29
PH12014502041B1 (en) 2014-11-24
AU2013234014B2 (en) 2017-02-02
IN2014MN01755A (OSRAM) 2015-07-03
KR20190073597A (ko) 2019-06-26
CU20140109A7 (es) 2014-11-27
GT201400196A (es) 2017-09-28
TN2014000357A1 (en) 2015-12-21
KR102241111B1 (ko) 2021-04-15
WO2013136254A1 (en) 2013-09-19
US9827247B2 (en) 2017-11-28
CA2865167C (en) 2019-08-06
ZA201406186B (en) 2016-06-29
US20170101408A1 (en) 2017-04-13
CA2865167A1 (en) 2013-09-19
AP2014008009A0 (en) 2014-10-31
MA37400B1 (fr) 2019-11-29
BR112014022713B1 (pt) 2021-09-08
KR20190100472A (ko) 2019-08-28
GEP201706774B (en) 2017-11-27
PH12014502040A1 (en) 2014-11-24
AU2017200493A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
CL2014002411A1 (es) Compuestos derivados de 5-(aril-amino)-1-fenilpirido[4,3-d]pirimidina-2,4,7(1h,3h,4ah)-triona, inhibidores de mek; composicion farmaceutica; y su uso en trastornos inflamatorios, autoinmunes com,o anrtritis reumatoide o esclerosis multiple, hiperproliferativas como leucemias, neoplasmas o carcinomas
CO7010837A2 (es) Compuestos derivados de 2-amino,6fenil pirido[2,3-d]pirimidina sustituidos utiles como inhibidores de quinasa raf
ME03301B (me) Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак)
EP2751112A4 (en) SUBSTITUTED PYRAZOLO [3,4-D] PYRIMIDINE AND ITS USE
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
DK3345907T3 (da) Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
CL2013001289A1 (es) Compuestos derivados de n-[2-oxo-5-fenil-piperidin-3-il]-[2’-oxo-espiro[ciclopenta[b]piridin-6,3’-pirrol[2,3-b]piridina] o 6’-oxo-espiro[ciclopenta[b]piridin-6,5’-pirrol[2,3-d]pirimidina]]-3-carboxamida, antagonistas de receptor del cgrp; composicion farmaceutica; y su uso para tratar la cefalea migrañosa.
CL2014001090A1 (es) Compuestos derivados de oxazolidinona biciclica; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis y dislipidemia.
CL2013001412A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina y de pirrolo[2,3-d]pirimidina sustituidos con ciclobutilo; inhibidores de jaks; composicion farmaceutica que lo comprende; utiles en el tratamiento de enfermedades autoinmunes, cancer, un trastorno mieloproliferativo, enfermedades inflamatorias, entre otras.
WO2015061247A3 (en) Heteroaryl compounds as btk inhibitors and uses thereof
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
SI3483163T1 (sl) derivati triazolo(4,5-d)pirimidina kot antagonisti receptorja cb2
IL240877A0 (en) History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them
GEP20186841B (en) Stabilized crystal of tipiracil hydrochloride, and crystallization method for same
EP3096762C0 (en) PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL COMPOUNDS
DK3596080T3 (da) Farmakologisk aktive alicyclisk-substitueret pyrazolo[1,5-a]pyrimidin-derivater
IL244817A0 (en) Transmuted pyrimidine compounds and their use as syk inhibitors
CO6801756A2 (es) Derivas de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritimia
EP2829582A4 (en) LABELING COMPOSITION MARKING AND MARKING PROMOTION THEREWITH
EP3036260A4 (en) Bruton's tyrosine kinase as anti-cancer drug target
SI2948443T1 (sl) Novi pirimidinski derivati kot inhibitorji fosfodiesteraze 10 (PDE-10)
CL2015001397A1 (es) Compuestos derivados de 4-amino-7,8-dihidropirimido[5,4-f][1,4]oxazepin-5(6h)-ona, inhibidores de diacilglicerol aciltransferasa; composicion farmaceutica y el uso en el tratamiento de la obesidad.
IL231934A (en) 4-Amino-3-Phenylamino-6-Phenylpyrazolo (4,3-d) Pyramidine derivatives, their production and use as active antiviral substances
Al-Daghman One of the indications of addition in the Quranic context Manifestations of the intention of the appointment and the ratio by adding the pronoun (ha) to the formula (verbs) in the light of appropriate knowledge
Sarikhani et al. Juridical Study of the Condition for